Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats

Nutrition and Metabolism

Volumn 10, Issue 1, 2013, Pages

  Hsieh, Feng Ching ^a,b   Lee, Chia Lin ^b   Chai, Chee Yin ^c   Chen, Wan Tzu ^c   Lu, Ying Chen ^d   Wu, Ching Shuang ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b Genmont Biotech Inc   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

Author keywords

Hepatic steatosis; High fructose diet; Insulin resistance; Lactobacillus reuteri GMNL 263; Type 2 diabetes

Indexed keywords

ANTIOXIDANT; C PEPTIDE; ELVOL6 PROTEIN; FAS ANTIGEN; FRUCTOSE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE TRANSPORTER 4; GLYCOSYLATED HEMOGLOBIN; INCRETIN; INSULIN; INTERLEUKIN 6; LACTOBACILLUS REUTERI GMNL 263; LEPTIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROBIOTIC AGENT; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BIFIDOBACTERIUM; CLOSTRIDIUM; CONTROLLED STUDY; FATTY LIVER; FECES MICROFLORA; GENE EXPRESSION; GLUCOSE INTAKE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTOBACILLUS; LACTOBACILLUS REUTERI; LIPID BLOOD LEVEL; LIPID LIVER LEVEL; LIVER INJURY; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; RAT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

BIFIDOBACTERIUM; CLOSTRIDIUM; LACTOBACILLUS; LACTOBACILLUS REUTERI; RATTUS;

EID: 84876087039     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-10-35     Document Type: Article

References (69)

1. Prevention of type 1 diabetes: from the view point of beta cell damage. Kawasaki E, Abiru N, Eguchi K, Diabetes Res Clin Pract 2004 66 27 32 15563975
2. Diagnosis, classification, and pathogenesis of diabetes mellitus. Lebovitz HE, J Clin Psychiatry 2001 62 5 9 11806489 (Pubitemid 34052251)
3. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik SL, Diabetes 2005 54 97 S107 10.2337/diabetes.54.suppl-2.S97 16306347 (Pubitemid 43343337)
4. Clinical review 124: Diabetic dyslipidemia: causes and consequences. Goldberg IJ, J Clin Endocrinol Metab 2001 86 965 71 10.1210/jc.86.3.965 11238470 (Pubitemid 32322966)
5. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Kahn CR, Diabetes 1994 43 84 066
6. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Wild SH, Roglic G, Green A, Sicree R, King H, Diabetes Care 2004 27 1047 1053 10.2337/diacare.27.5.1047 15111519 (Pubitemid 38579764)
7. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. King H, Aubert RE, Herman WH, Diabetes Care 1998 21 1414 1431 10.2337/diacare.21.9.1414 9727886 (Pubitemid 28405191)
8. Why Syndrome X? From Harold Himsworth to the insulin resistance syndrome. Reaven GM, Cell Metab 2005 1 9 14 10.1016/j.cmet.2004.12.001 16054040 (Pubitemid 43960585)
9. Etiology of insulin resistance. Petersen KF, Shulman GL, Am J Med 2006 119 10 S16 10.1016/j.amjmed.2006.01.009 16563942
10. Association of nonalcoholic fatty liver disease with insulin resistance. Marchesini G, Brizi M, Morselli-Labate AM, Am J Med 1999 107 450 455 10.1016/S0002-9343(99)00271-5 10569299 (Pubitemid 29528333)
11. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Robertson G, Leclercq I, Farrell GC, Am J Physiol Gastrointest Liver Physiol 2001 281 1135 G1139 11668021
12. Health, probiotics, and inflammation. Mengheri E, J Clin Gastroenterol 2008 42 177 S178 18685508
13. Probiotics and prevention of allergic disease. Kopp MV, Salfeld P, Curr Opin Clin Nutr Metab Care 2009 12 298 303 10.1097/MCO.0b013e32832989a3 19318939
14. Human gut microbiota and its relationship to health and disease. Wallace TC, Guarner F, Madsen K, Cabana MD, Nutr Rev 2011 69 392 403 10.1111/j.1753-4887.2011.00402.x 21729093
15. Prevention of onset in an insulin-dependent diabetes mellitus model, NOD mice, by oral feeding of Lactobacillus casei. Matsuzaki T, Nagata Y, Kado S, Uchida K, APMIS 1997 105 643 649 10.1111/j.1699-0463.1997.tb05066.x 9298104 (Pubitemid 27380828)
16. Antidiabetic effects of an oral administration of Lactobacillus casei in a non-insulin-dependent diabetes mellitus (NIDDM) model using KK-Ay mice. Matsuzaki T, Yamazaki R, Hashimoto S, Yokokura T, Endocr J 1997 44 357 365 10.1507/endocrj.44.357 9279510 (Pubitemid 27310421)
17. Antidiabetic effect of Lactobacillus GG in streptozotocin-induced diabetic rats. Tabuchi M, Ozaki M, Tamura A, Yamada N, Biosci Biotechnol Biochem 2003 67 67 1421 1424 12843677 (Pubitemid 39251845)
18. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Cani P, Neyrinck N, Fava F, Knauf C, Diabetologia 2007 50 2374 2383 10.1007/s00125-007-0791-0 17823788 (Pubitemid 47512397)
19. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Yadav H, Jain S, Sinha SR, Nutrition 2007 23 62 68 10.1016/j.nut.2006.09.002 17084593 (Pubitemid 44959762)
20. Sinha, PR: Oral administration of dahi containing probiotic Lactobacillus acidophilus and Lactobacillus casei delayed the progression of streptozotocin-induced diabetes in rats. Yadav H, Jain S, J Dairy Res 2008 75 189 195 18474136 (Pubitemid 351670283)
21. Effect of Lactobacillus reuteri GMNL-263 treatment on renal fibrosis in diabetic rats. Lu YC, Yin LT, Chang WT, Huang JS, J Biosci Bioeng 2010 110 709 715 10.1016/j.jbiosc.2010.07.006 20691633
22. Molecular and microbiological analysis of caecal microbiota in rats fed with diets supplemented either with prebiotics or probiotics. Montesi A, García-Albiach R, Pozuelo MJ, Pintado C, Goñi I, Rotger R, Int J Food Microbiol 2005 98 281 289 10.1016/j.ijfoodmicro.2004.06.005 15698689 (Pubitemid 40215386)
23. Effects of a unique conjugate of alpha-lipoic acid and γ-linolenic acid on insulin action in obese Zucker rats. Peth JA, Kinnick TR, Youngblood EB, Tritschler HJ, Henriksen EJ, Am J Physiol Regul Integr Comp Physiol 2000 278 453 R459 10666147
24. A simple method for the isolation and purification of total lipids from animal tissues. Folch J, Lees M, Sloane-Stanley G, J Biol Chem 1957 226 497 509 13428781
25. Fructose, insulin resistance, and metabolic dyslipidemia. Basciano H, Federico L, Adeli K, Nutr Metab (Lond) 2005 2 5 10.1186/1743-7075-2-5 (Pubitemid 40412656)
26. The prevention of type 2 diabetes mellitus: recent advances. Younis N, Soran H, Farook S, QJM 2004 97 451 455 10.1093/qjmed/hch077 15208433 (Pubitemid 38967419)
27. Perspectives on the role of the human gut microbiota and its modulation by pro-and prebiotics. Steer T, Carpenter H, Tuohy K, Gibson GR, Nutrition Research Reviews 2000 13 229 254 10.1079/095442200108729089 19087441 (Pubitemid 32125097)
28. Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feeding. Cani P, Delzenne NM, Amar J, Burcelin R, Pathol Biol 2008 56 305 309 10.1016/j.patbio.2007.09.008 18178333
29. Critical evaluation of probiotic activity of lactic acid bacteria and their effects. Heczko PB, Strus M, Kochan P, J Physiol Pharmacol 2006 57 5 12 17244950 (Pubitemid 46569845)
30. Effect of Lactobacillus gasseri BNR17 on blood glucose levels and body weight in a mouse model of type 2 diabetes. Yun SI, Park HO, Kang JH, J Appl Microbiol 2009 107 1681 1686 10.1111/j.1365-2672.2009.04350.x 19457033
31. Gut flora in health and disease. Guarner F, Malagelada JR, The Lancet 2003 361 512 519 10.1016/S0140-6736(03)12489-0 (Pubitemid 36173720)
32. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and methanogens in anorexic patients. Armougom F, Henry M, Vialettes B, Raccah D, Raoult D, Plos One 2009 4 7125 10.1371/journal.pone.0007125 19774074
33. Weight gain and the risk of developing insulin resistance syndrome. Everson SA, Goldberg DE, Helmrich SP, Lakka TA, Diabetes Care 1998 21 1637 1643 10.2337/diacare.21.10.1637 9773723 (Pubitemid 28449800)
34. Adipose tissue and atherosclerosis: exploring the connection. Fantuzzi G, Mazzone T, Arterioscler Thromb Vasc Biol 2007 27 996 1003 10.1161/ATVBAHA.106. 131755 17303782 (Pubitemid 46641984)
35. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Group DS, Lancet 1999 354 617 621 10466661
36. Regulation of leptin production in humans. Fried SK, Ricci MR, Russell CD, Laferrere B, J Nutr 2000 130 3127S 3131S 11110887 (Pubitemid 32005354)
37. Estradiol Supplementation Helps Overcome Central Leptin Resistance of Ovariectomized Mice on a High Fat Diet. Matyskova R, Zelezna B, Maixnerova J, Koutova D, Haluzik M, Maletinska L, Horm Metab Res 2010 42 182 186 10.1055/s-0029-1243250 20049675
38. Adipokines and insulin resistance. Rabe K, Lehrke M, Parhofer KG, Broedl UC, Mol Med 2008 14 741 751 19009016
39. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. Polonsky KS, Licinio-Paixao J, Given BD, Pugh W, Rue P, Galloway J, Karrison T, Frank B, J Clin Invest 1986 77 98 105 10.1172/JCI112308 3511094 (Pubitemid 16101207)
40. Assays for insulin, proinsulin(s) and C-peptide. Clark PM, Ann Clin Biochem 1999 36 541 564 10505204 (Pubitemid 29410707)
41. Relationship between serum adiponectin and leptin concentrations and body fat distribution. Park KG, Park KS, Kim MJ, Kim HS, Diabetes Res Clin Pract 2004 63 135 142 10.1016/j.diabres.2003.09.010 14739054 (Pubitemid 38096359)
42. New developments in the incretin concept. Creutzfeldt W, Ebert R, Diabetologia 1985 28 565 573 3902545 (Pubitemid 15017390)
43. The glucagon-like peptides. Kieffer TJ, Habener JF, Endocr Rev 1999 20 876 913 10.1210/er.20.6.876 10605628 (Pubitemid 30647076)
44. The physiology of glucagon-like peptide 1. Holst JJ, Physiol Rev 2007 87 1409 1439 10.1152/physrev.00034.2006 17928588 (Pubitemid 350041474)
45. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ, Diabetes 2001 50 609 613 10.2337/diabetes.50.3. 609 11246881 (Pubitemid 32195226)
46. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W, J Clin Invest 1993 91 301 307 10.1172/JCI116186 8423228 (Pubitemid 23037285)
47. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF, Andersen DK, Regul Pept 1994 51 63 74 10.1016/0167-0115(94) 90136-8 8036284 (Pubitemid 24119981)
48. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Kjems LL, Holst JJ, Volund A, Madsbad S, Diabetes 2003 52 380 386 12540611 (Pubitemid 36173193)
49. Superoxide production by mitochondria of insulin-sensitive tissues: mechanistic differences and effect of early diabetes. Herlein JA, Fink BD, Sivitz WI, Metab Clin Exp 2010 59 247 257 10.1016/j.metabol.2009.07.021 19765776
50. Resveratrol inhibits nonalcoholic fatty liver disease in rats. Bujanda L, Hijona E, Larzabal M, Beraza M, BMC Gastroenterol 2008 8 40 47 10.1186/1471-230X-8-40 18782455
51. Increased lipid peroxidation and impaired antioxidant enzyme function is associated with pathological liver injury in experimental alcoholic liver disease in rats fed diets high in corn oil and fish oil. Polavarapu R, Spitz DR, Sim JE, Follansbee MH, Hepatology 1998 27 1317 1323 10.1002/hep.510270518 9581686 (Pubitemid 28227859)
52. Increased oxidative stress in obesity and its impact on metabolic syndrome. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I, J Clin Invest 2004 114 1752 1761 15599400 (Pubitemid 40385531)
53. Inflammation, stress, and diabetes. Wellen KE, Hotamisligil GS, J Clin Invest 2005 115 1111 1119 15864338 (Pubitemid 40629025)
54. Insulin resistance is a cellular antioxidant defense mechanism. Hoehn KL, Salmon AB, Hohnen-Behrens C, Turner N, Proc Natl Acad Sci USA 2009 106 17787 17792 10.1073/pnas.0902380106 19805130
55. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM, J Clin Invest 1994 94 1543 1549 10.1172/JCI117495 7523453
56. The metabolic syndrome. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Endocr Rev 2008 29 777 822 10.1210/er.2008-0024 18971485
57. Genetic control of de novo lipogenesis: role in diet-induced obesity. Strable MS, Ntambi JM, Crit Rev Biochem Mol Biol 2010 45 199 214 10.3109/10409231003667500 20218765
58. Dietary green tea extract lowers plasma and hepatic triglycerides and decreases the expression of sterol regulatory element-binding protein-1c mRNA and its responsive genes in fructose-fed, ovariectomized rats. Shrestha S, Ehlers SJ, Lee JY, Fernandez ML, Koo SI, J Nutr 2009 139 640 645 10.3945/jn.108.103341 19193814
59. Elovl6: a new player in fatty acid metabolism and insulin sensitivity. Matsuzaka T, Shimano H, J Mol Med (Berl) 2009 87 379 384 10.1007/s00109-009- 0449-0
60. Mouse Elovl-6 is an SREBP target. Kumadaki S, Matsuzaka T, Kato T, Yahagi N, Biochem Biophys Res Commun 2008 368 261 266 10.1016/j.bbrc.2008.01.075 18226595
61. The pleiotropic functions of peroxisome proliferator-activated receptor gamma. Debril MB, Renaud JP, Fajas L, Auwerx J, J Mol Med 2001 79 30 47 10.1007/s001090000145 11327101 (Pubitemid 32250021)
62. GLUT4 gene regulation and manipulation. Charron MJ, Katz EB, Olson AL, J Biol Chem 1999 274 3253 3256 10.1074/jbc.274.6.3253 9920861 (Pubitemid 29077156)
63. Regulated membrane trafficking of the insulin- responsive glucose transporter 4 in adipocytes. Watson RT, Kanzaki M, Pessin JE, Endocr Rev 2004 25 177 204 10.1210/er.2003-0011 15082519 (Pubitemid 38501393)
64. PPARγ induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes. Wu Z, Xie Y, Morrison RF, Bucher NLR, Farmer SR, Journal of Clinical Investigation 1998 101 22 32 10.1172/JCI1244 9421462 (Pubitemid 28058899)
65. Steatohepatitis: a tale of two hits? Day CP, James OF, Gastroenterology 1998 114 842 845 10.1016/S0016-5085(98)70599-2 9547102 (Pubitemid 28160420)
66. Correlation of abdominal fat accumulation and liver steatosis: importance of ultrasonographic and anthropometric measurements. Sabir N, Sermez Y, Kazil S, Zencir M, Eur J Ultrasound 2001 14 121 128 10.1016/S0929-8266(01)00153-7 11704429 (Pubitemid 33026505)
67. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Shang J, Chen LL, Xiao FX, Sun H, Ding HC, Xiao H, Acta Pharmacol Sin 2008 29 698 706 10.1111/j.1745-7254.2008.00807.x 18501116 (Pubitemid 351799479)
68. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Andreasen AS, Larsen N, Pedersen-Skovsgaard T, Berg RM, Møller K, Svendsen KD, Jakobsen M, Pedersen BK, Br J Nutr 2010 104 1831 1838 10.1017/S0007114510002874 20815975
69. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V, Nutrition 2012 28 539 543 10.1016/j.nut.2011.08.013 22129852